Malignant Esophageal Neoplasm — Trials

Malignant Esophageal Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,926 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 518
Recruiting: 302
Ph III recruiting: 41
Growth YoY: +2.4%
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 28.5%
Trials / 1,000 deaths: 32.3 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (169)

clinicaltrialsPublishedShowing 151–200 of 401 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05007145	PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma(REVO)	unknown	Phase 2	92	Fujian Cancer HospitalOTHER_GOV	1	Dec 21, 2021	clinicaltrials
NCT04506138	Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma	unknown	Phase 1 / Phase 2	46	Zhejiang Cancer HospitalOTHER	1	Dec 14, 2021